Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Give money, supplies to help stock Wake County classrooms
Recommended
What to know about Shearon Harris Nuclear Plant, emergency plans
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
14.55
+0.35 (+2.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
January 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Gold Rises Over 1%; Elys Game Technology Shares Spike Higher
December 27, 2022
U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
Expert Ratings for KalVista Pharma
October 05, 2022
KalVista Pharma (NASDAQ:KALV) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Where KalVista Pharma Stands With Analysts
October 05, 2022
Analysts have provided the following ratings for KalVista Pharma (NASDAQ:KALV) within the last quarter:
Via
Benzinga
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
December 27, 2022
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 27, 2022
Via
Benzinga
Major Indexes Falter As Rocky Year Wraps Up
December 27, 2022
Stocks are struggling to build on their morning gains as investors began to waver on the possibility of a
Via
Talk Markets
Dow Rises 100 Points; Crude Oil Rises Over 1%
December 27, 2022
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 27, 2022
Via
Benzinga
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
December 27, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 08, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
November 14, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 07, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
October 31, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
October 19, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
October 17, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
October 07, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%
October 06, 2022
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading.
Via
Benzinga
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
October 05, 2022
Wednesday saw 127 companies set new 52-week lows.
Via
Benzinga
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
October 05, 2022
Losers
Via
Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
October 04, 2022
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
October 04, 2022
The company scrapped its hereditary angioedema drug due to safety issues.
Via
Investor's Business Daily
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 04, 2022
On Tuesday, 44 companies hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.